CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes

By sjmartinez • February 11, 2024

Jilani S, Saco JD, Mugarza E, Pujol-Morcillo A, Chokry J, Ng C, Abril-Rodriguez G, Berger-Manerio D, Pant A, Hu J, Gupta R, Vega-Crespo A, Baselga-Carretero I, Chen JM, Shin DS, Scumpia P, Radu RA, Chen Y, Ribas A, Puig-Saus C. CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes. Nat Commun. 2024 Feb 9;15(1):1244. doi: 10.1038/s41467-024-45221-2. PMID: 38336975; PMCID: PMC10858182.

Tags: Dermatology, Hematology/Oncology, Publications, Veterans Administration

Is Cumulative Life Course Impairment Considered in Psoriasis Management? A Multinational Survey of People with Psoriasis and Healthcare Professionals

Matthews R, Armstrong AW, Augustin M, Baker C, Carrascosa JM, Kirby B, Langley R, McBride S, Reich A, Romiti R, Sampogna F, Warren RB. Is[...]

T cell-macrophage interactions in tuberculosis: What we’ve got here is failure to communicate

Mortensen R, Arlehamn CSL, Coler RN, Gerner MY, Goletti D, Lewinsohn DA, Modlin RL, Musvosvi M, Rengarajan J, Urdahl KB, Walzl G, Behar SM, Barber[...]

Joint Position Statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on Routine Testing for Latent Tuberculosis Infection Prior To and During Treatment of Psoriasis Patients with IL-17 or IL-23 Inhibitors

Blauvelt A, Strober BE, Eakin GS, McCormick Howard L, Langan C, van de Kerkhof PCM, Puig L, Lebwohl MG, Romiti R, Armstrong AW, Choon SE,[...]